PD-1与PD-L1的6大区别

参考文献：

1. Cao W,Chen H-D, Yu Y-W, et al. Changing profiles of cancer burden worldwide and inChina: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J(Engl), 2021, 134(7): 783.
2. Non-SmallCell Lung Cancer Treatment (PDQ®): Patient Version.https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
3. Xie T,Wang S, Xing P. Analysis of the Correlation between Molecular StructuralDifferences of PD-1/PD-L1 Inhibitors and Adverse Events[J]. Zhongguo fei ai zazhi = Chinese journal of lung cancer, 2020, 23(7): 603-608.
4. ImmunoglobulinG (IgG): Structure, Subclasses, Functions.https://microbeonline.com/igg-antibody-structure-subclasses-functions-and-clinical-significance/
5. Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition forCancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome[J].Frontiers in pharmacology, 2017, 8: 561-561.
6. Córdova-BahenaL, Velasco-Velázquez M A. Anti-PD-1 And Anti-PD-L1 Antibodies as ImmunotherapyAgainst Cancer: A Structural Perspective[J]. Rev Invest Clin, 2020, 73(1):008-016.
7. Lee H T,Lee S H, Heo Y-S. Molecular Interactions of Antibody Drugs Targeting PD-1,PD-L1, and CTLA-4 in Immuno-Oncology[J]. Molecules (Basel, Switzerland), 2019,24(6): 1190.
8. De SousaLinhares A, Battin C, Jutz S, et al. Therapeutic PD-L1 antibodies are moreeffective than PD-1 antibodies in blocking PD-1/PD-L1 signaling[J]. ScientificReports, 2019, 9(1): 11472.
9. Leal T,Wang Y, Dowlati A, et al. Randomized phase II clinical trial ofcisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumabas frontline therapy for extensive-stage small cell lung cancer (ES-SCLC):ECOG-ACRIN EA5161[J]. Journal of Clinical Oncology, 2020, 38(15_suppl):9000-9000.
10. Rudin CM, Awad M M, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide andPlatinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer:Randomized, Double-Blind, Phase III KEYNOTE-604 Study[J]. Journal of clinicaloncology : official journal of the American Society of Clinical Oncology, 2020,38(21): 2369-2379.
11. Horn L,Mansfield A S, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy inExtensive-Stage Small-Cell Lung Cancer[J]. New England Journal of Medicine,2018, 379(23): 2220-2229.
12. Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plusplatinum-etoposide versus platinum-etoposide alone in first-line treatment ofextensive-stage small-cell lung cancer (CASPIAN): updated results from arandomised, controlled, open-label, phase 3 trial[J]. Lancet Oncol, 2021,22(1): 51-65.
13. 倪军, 张力. 肿瘤免疫治疗相关不良反应研究进展[J]. 中华内科杂志, 2021, 60(01): 84-89.
14. Ghosh C,Luong G, Sun Y. A snapshot of the PD-1/PD-L1 pathway[J]. Journal of Cancer,2021, 12(9): 2735-2746.